Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often underdiagnosed due to multifactorial pathophysiology and a historic lack of standard diagnostic criteria. Identification of the multi-...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2023-06, Vol.58 (6), p.625-634 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 634 |
|---|---|
| container_issue | 6 |
| container_start_page | 625 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 58 |
| creator | Mahmoudjafari, Zahra Alencar, Maritza C. Alexander, Maurice D. Johnson, Darren J. Yeh, Jason Evans, Misty D. |
| description | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often underdiagnosed due to multifactorial pathophysiology and a historic lack of standard diagnostic criteria. Identification of the multi-hit hypothesis and the key role of the complement system, particularly the lectin pathway of complement, has led to development of treatments targeting the underlying pathogenesis of HSCT-TMA. Additional research is ongoing to investigate the efficacy and safety of these targeted therapies in patients with HSCT-TMA. Advanced practice providers (APPs; nurse practitioners and physician assistants) and pharmacists are critical members of the multidisciplinary HSCT team and ensure management of patients throughout the continuum of care. Additionally, pharmacists and APPs can improve patient care through medication management of complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives to improve outcomes. Understanding the presentation, prognosis, pathophysiology, and treatment options for HSCT-TMA can improve each of these efforts.
Collaborative practice model for monitoring and care of HSCT-TMA. Advanced practice providers and pharmacists contribute to many aspects of patient care in transplant centers, including medication management for complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives. HSCT-TMA is a severe and potentially life-threatening complication that is often underdiagnosed. The collaboration of a multidisciplinary team of advanced practice providers, pharmacists, and physicians can optimize recognition, diagnosis, management, and monitoring of patients with HSCT-TMA, thereby improving outcomes for these patients. |
| doi_str_mv | 10.1038/s41409-023-01951-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10247375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2801980147</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-a0bb8320354c69ddf8ee00eb6661bab6cb88081a921da9e768cf5fe843d6cced3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERYeBF2CBIrFhE-q_OM4KoQpopUrdwNq6cW5mXCV2sD0j9RH61ng6bflZdGHZ0v3O8b33EPKO0U-MCn2WJJO0qykXNWVdw2rxgqyYbFXdCNW8JCvKla6FUN0peZ3SDaVMStq8IqeipU3XCr0idxc4Qw5LcJidrVLGubI4TVWO4NMygc-QXfA1pBSsg4xDlbcxzH048LOzMYDfuLBA3t5W4A9lrGKYsApjBcMevC2aJYItAiyPsHcDxnTPLluIM1iXcnpDTkaYEr59uNfk57evP84v6qvr75fnX65qK9sm10D7XgtORSOt6oZh1IiUYq-UYj30yvZaU82g42yADlul7diMqKUYlC2diDX5fPRddv2Mg0VfRp3MEt0M8dYEcObfindbswl7wyiXrWib4vDxwSGGXztM2cwuHZYGHsMuGa5LHOUUek0-_IfehF30Zb5ClXR4JyQvFD9SZZkpRRyfumHUHKI2x6hNidrcR21EEb3_e44nyWO2BRBHIJWS32D88_cztr8BFqe5wg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2826829342</pqid></control><display><type>article</type><title>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Mahmoudjafari, Zahra ; Alencar, Maritza C. ; Alexander, Maurice D. ; Johnson, Darren J. ; Yeh, Jason ; Evans, Misty D.</creator><creatorcontrib>Mahmoudjafari, Zahra ; Alencar, Maritza C. ; Alexander, Maurice D. ; Johnson, Darren J. ; Yeh, Jason ; Evans, Misty D.</creatorcontrib><description>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often underdiagnosed due to multifactorial pathophysiology and a historic lack of standard diagnostic criteria. Identification of the multi-hit hypothesis and the key role of the complement system, particularly the lectin pathway of complement, has led to development of treatments targeting the underlying pathogenesis of HSCT-TMA. Additional research is ongoing to investigate the efficacy and safety of these targeted therapies in patients with HSCT-TMA. Advanced practice providers (APPs; nurse practitioners and physician assistants) and pharmacists are critical members of the multidisciplinary HSCT team and ensure management of patients throughout the continuum of care. Additionally, pharmacists and APPs can improve patient care through medication management of complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives to improve outcomes. Understanding the presentation, prognosis, pathophysiology, and treatment options for HSCT-TMA can improve each of these efforts.
Collaborative practice model for monitoring and care of HSCT-TMA. Advanced practice providers and pharmacists contribute to many aspects of patient care in transplant centers, including medication management for complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives. HSCT-TMA is a severe and potentially life-threatening complication that is often underdiagnosed. The collaboration of a multidisciplinary team of advanced practice providers, pharmacists, and physicians can optimize recognition, diagnosis, management, and monitoring of patients with HSCT-TMA, thereby improving outcomes for these patients.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-023-01951-3</identifier><identifier>PMID: 37059738</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/1541 ; 692/700/139 ; 692/700/565 ; Cell Biology ; Complement system ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; Humans ; Internal Medicine ; Longitudinal Studies ; Medicine ; Medicine & Public Health ; Pathogenesis ; Pathophysiology ; Patients ; Pharmacists ; Prognosis ; Public Health ; Quality control ; Review ; Review Article ; Stem cell transplantation ; Stem Cells ; Thrombotic Microangiopathies - diagnosis ; Thrombotic Microangiopathies - etiology ; Thrombotic Microangiopathies - therapy ; Thrombotic microangiopathy ; Transplantation</subject><ispartof>Bone marrow transplantation (Basingstoke), 2023-06, Vol.58 (6), p.625-634</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-a0bb8320354c69ddf8ee00eb6661bab6cb88081a921da9e768cf5fe843d6cced3</citedby><cites>FETCH-LOGICAL-c475t-a0bb8320354c69ddf8ee00eb6661bab6cb88081a921da9e768cf5fe843d6cced3</cites><orcidid>0000-0002-3168-2521</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37059738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahmoudjafari, Zahra</creatorcontrib><creatorcontrib>Alencar, Maritza C.</creatorcontrib><creatorcontrib>Alexander, Maurice D.</creatorcontrib><creatorcontrib>Johnson, Darren J.</creatorcontrib><creatorcontrib>Yeh, Jason</creatorcontrib><creatorcontrib>Evans, Misty D.</creatorcontrib><title>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often underdiagnosed due to multifactorial pathophysiology and a historic lack of standard diagnostic criteria. Identification of the multi-hit hypothesis and the key role of the complement system, particularly the lectin pathway of complement, has led to development of treatments targeting the underlying pathogenesis of HSCT-TMA. Additional research is ongoing to investigate the efficacy and safety of these targeted therapies in patients with HSCT-TMA. Advanced practice providers (APPs; nurse practitioners and physician assistants) and pharmacists are critical members of the multidisciplinary HSCT team and ensure management of patients throughout the continuum of care. Additionally, pharmacists and APPs can improve patient care through medication management of complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives to improve outcomes. Understanding the presentation, prognosis, pathophysiology, and treatment options for HSCT-TMA can improve each of these efforts.
Collaborative practice model for monitoring and care of HSCT-TMA. Advanced practice providers and pharmacists contribute to many aspects of patient care in transplant centers, including medication management for complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives. HSCT-TMA is a severe and potentially life-threatening complication that is often underdiagnosed. The collaboration of a multidisciplinary team of advanced practice providers, pharmacists, and physicians can optimize recognition, diagnosis, management, and monitoring of patients with HSCT-TMA, thereby improving outcomes for these patients.</description><subject>692/699/1541</subject><subject>692/700/139</subject><subject>692/700/565</subject><subject>Cell Biology</subject><subject>Complement system</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Longitudinal Studies</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pathogenesis</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Pharmacists</subject><subject>Prognosis</subject><subject>Public Health</subject><subject>Quality control</subject><subject>Review</subject><subject>Review Article</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Thrombotic Microangiopathies - diagnosis</subject><subject>Thrombotic Microangiopathies - etiology</subject><subject>Thrombotic Microangiopathies - therapy</subject><subject>Thrombotic microangiopathy</subject><subject>Transplantation</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1u1DAUhS1ERYeBF2CBIrFhE-q_OM4KoQpopUrdwNq6cW5mXCV2sD0j9RH61ng6bflZdGHZ0v3O8b33EPKO0U-MCn2WJJO0qykXNWVdw2rxgqyYbFXdCNW8JCvKla6FUN0peZ3SDaVMStq8IqeipU3XCr0idxc4Qw5LcJidrVLGubI4TVWO4NMygc-QXfA1pBSsg4xDlbcxzH048LOzMYDfuLBA3t5W4A9lrGKYsApjBcMevC2aJYItAiyPsHcDxnTPLluIM1iXcnpDTkaYEr59uNfk57evP84v6qvr75fnX65qK9sm10D7XgtORSOt6oZh1IiUYq-UYj30yvZaU82g42yADlul7diMqKUYlC2diDX5fPRddv2Mg0VfRp3MEt0M8dYEcObfindbswl7wyiXrWib4vDxwSGGXztM2cwuHZYGHsMuGa5LHOUUek0-_IfehF30Zb5ClXR4JyQvFD9SZZkpRRyfumHUHKI2x6hNidrcR21EEb3_e44nyWO2BRBHIJWS32D88_cztr8BFqe5wg</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Mahmoudjafari, Zahra</creator><creator>Alencar, Maritza C.</creator><creator>Alexander, Maurice D.</creator><creator>Johnson, Darren J.</creator><creator>Yeh, Jason</creator><creator>Evans, Misty D.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3168-2521</orcidid></search><sort><creationdate>20230601</creationdate><title>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists</title><author>Mahmoudjafari, Zahra ; Alencar, Maritza C. ; Alexander, Maurice D. ; Johnson, Darren J. ; Yeh, Jason ; Evans, Misty D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-a0bb8320354c69ddf8ee00eb6661bab6cb88081a921da9e768cf5fe843d6cced3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>692/699/1541</topic><topic>692/700/139</topic><topic>692/700/565</topic><topic>Cell Biology</topic><topic>Complement system</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Longitudinal Studies</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pathogenesis</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Pharmacists</topic><topic>Prognosis</topic><topic>Public Health</topic><topic>Quality control</topic><topic>Review</topic><topic>Review Article</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Thrombotic Microangiopathies - diagnosis</topic><topic>Thrombotic Microangiopathies - etiology</topic><topic>Thrombotic Microangiopathies - therapy</topic><topic>Thrombotic microangiopathy</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahmoudjafari, Zahra</creatorcontrib><creatorcontrib>Alencar, Maritza C.</creatorcontrib><creatorcontrib>Alexander, Maurice D.</creatorcontrib><creatorcontrib>Johnson, Darren J.</creatorcontrib><creatorcontrib>Yeh, Jason</creatorcontrib><creatorcontrib>Evans, Misty D.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahmoudjafari, Zahra</au><au>Alencar, Maritza C.</au><au>Alexander, Maurice D.</au><au>Johnson, Darren J.</au><au>Yeh, Jason</au><au>Evans, Misty D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>58</volume><issue>6</issue><spage>625</spage><epage>634</epage><pages>625-634</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often underdiagnosed due to multifactorial pathophysiology and a historic lack of standard diagnostic criteria. Identification of the multi-hit hypothesis and the key role of the complement system, particularly the lectin pathway of complement, has led to development of treatments targeting the underlying pathogenesis of HSCT-TMA. Additional research is ongoing to investigate the efficacy and safety of these targeted therapies in patients with HSCT-TMA. Advanced practice providers (APPs; nurse practitioners and physician assistants) and pharmacists are critical members of the multidisciplinary HSCT team and ensure management of patients throughout the continuum of care. Additionally, pharmacists and APPs can improve patient care through medication management of complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives to improve outcomes. Understanding the presentation, prognosis, pathophysiology, and treatment options for HSCT-TMA can improve each of these efforts.
Collaborative practice model for monitoring and care of HSCT-TMA. Advanced practice providers and pharmacists contribute to many aspects of patient care in transplant centers, including medication management for complex regimens; transplant education for patients, staff, and trainees; evidence-based protocol and clinical guideline development; assessment and reporting of transplant-related outcomes; and quality improvement initiatives. HSCT-TMA is a severe and potentially life-threatening complication that is often underdiagnosed. The collaboration of a multidisciplinary team of advanced practice providers, pharmacists, and physicians can optimize recognition, diagnosis, management, and monitoring of patients with HSCT-TMA, thereby improving outcomes for these patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37059738</pmid><doi>10.1038/s41409-023-01951-3</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3168-2521</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2023-06, Vol.58 (6), p.625-634 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10247375 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 692/699/1541 692/700/139 692/700/565 Cell Biology Complement system Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Humans Internal Medicine Longitudinal Studies Medicine Medicine & Public Health Pathogenesis Pathophysiology Patients Pharmacists Prognosis Public Health Quality control Review Review Article Stem cell transplantation Stem Cells Thrombotic Microangiopathies - diagnosis Thrombotic Microangiopathies - etiology Thrombotic Microangiopathies - therapy Thrombotic microangiopathy Transplantation |
| title | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A51%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hematopoietic%20stem%20cell%20transplantation-associated%20thrombotic%20microangiopathy%20and%20the%20role%20of%20advanced%20practice%20providers%20and%20pharmacists&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Mahmoudjafari,%20Zahra&rft.date=2023-06-01&rft.volume=58&rft.issue=6&rft.spage=625&rft.epage=634&rft.pages=625-634&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-023-01951-3&rft_dat=%3Cproquest_pubme%3E2801980147%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2826829342&rft_id=info:pmid/37059738&rfr_iscdi=true |